Print Friendly, PDF & Email

Respiratory Syncytial Virus (RSV) Vaccine


Source: Nature


Context: The US Food and Drug Administration (FDA) has approved the first-ever respiratory syncytial virus (RSV) vaccine, developed by UK-based pharmaceutical company GSK, for use in people aged 60 years and older.


About respiratory syncytial virus (RSV):

Topic Description
What is RSV? Respiratory syncytial virus (RSV) is a common virus that can cause mild to severe respiratory illness, especially in young children and older adults.
Transmission RSV spreads through respiratory secretions, such as from coughing or sneezing, or by touching contaminated surfaces or objects.
Symptoms RSV can cause symptoms such as coughing, wheezing, fever, runny nose, and difficulty breathing.
Venerable Infants, older adults, and people with weakened immune systems are most at risk for severe RSV infection.
How is RSV diagnosed? RSV can be diagnosed through a respiratory sample, such as from a nasal or throat swab, that is tested in a laboratory.
How is RSV treated? Treatment for RSV is mainly supportive, such as with fluids, oxygen therapy, and fever reducers. Severe cases may require hospitalization.